Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ITI 7000

Next Previous
Search
Drug Profile

ITI 7000

Alternative Names: ErbB2-LAMP vaccine - Immunomic Therapeutics; Her2-LAMP vaccine - Immunomic Therapeutics; ITI-7000

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomic Therapeutics
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Bladder cancer

Highest Development Phases

  • No development reported Bladder cancer

Most Recent Events

  • 28 May 2023 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Parenteral)
  • 09 Apr 2019 ITI 7000 is available for licensing as of 09 Apr 2019. https://www.immunomix.com/partnerships/
  • 03 Apr 2019 Preclinical trials in Bladder cancer in USA (Parenteral) before April 2019 (Immunomic Therapeutics pipeline, April 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top